A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC/OvCa after first-line chemotherapy added to standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or primary peritoneal carcinoma.

Trial Details

NCT ID
NCT04834544
Phase
PHASE2
Sponsor
Peking University Third Hospital
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • DCVAC/OvCa
  • Placebo
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Eighteen years of age or older at the time written informed consent is obtained
  • Newly diagnosed, histologically confirmed FIGO stage III or IV EOC (high-grade serous or high-grade endometrioid)
  • After primary debulking surgery or after interval debulking surgery; residual disease after surgery with optimal resection as R0 or R1 (R0 is defin…
  • Known BRCA status; if BRCA mutation status not known, results of BRCA testing must be available before randomization

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →